Latest Breaking News On - Rickard ljung - Page 1 : comparemela.com

Messenger RNA COVID-19 Vaccines Linked to Increased Risk of Vaginal Bleeding: Study

Messenger RNA COVID-19 Vaccines Linked to Increased Risk of Vaginal Bleeding: Study
theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesRickard ljungAshelley coleHarvey rischYale school of public healthProducts agencyBritish medicalAdverse event reporting systemRisks priorMedical products agencyEpoch timesYale schoolPublic health

COVID-19 s Lingering Threat: A Surge in a Rare and Dangerous Heart Condition

COVID-19 s Lingering Threat: A Surge in a Rare and Dangerous Heart Condition
theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.

United statesSharon nachmanRickard ljungSinai hospital smidt heart instituteJournal of the american medical associationColumbia universityUniversity of south floridaUs centers for diseaseSwedish medical products agencySouth floridaHeart inflammationHeart attacksYoung people theCedars sinai hospitalSmidt heart instituteMedical virology

Comparative effectiveness of bivalent BA 4-5 and BA 1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study

Objective To estimate the effectiveness of the bivalent mRNA booster vaccines containing the original SARS-CoV-2 and omicron BA.4-5 or BA.1 subvariants as the fourth dose against severe covid-19. Design Nationwide cohort analyses, using target trial emulation. Setting Denmark, Finland, Norway, and Sweden, from 1 July 2022 to 10 April 2023. Participants People aged ≥50 years who had received at least three doses of covid-19 vaccine (that is, a primary course and a first booster). Main outcome measures The Kaplan-Meier estimator was used to compare the risk of hospital admission and death related to covid-19 in people who received a bivalent Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) BA.4-5 or BA.1 mRNA booster vaccine as a fourth dose (second booster) with three dose (first booster) vaccinated people and between four dose vaccinated people. Results A total of 1 634 199 people receiving bivalent BA.4-5 fourth dose booster and 1 042 124 receiving bivalent BA.1 fourth

United kingdomNorth carolinaUnited statesNicklas pihlstrUlrike baumHinta meijerinkEmilia myrup thiessonRickard ljungJostein starrfeltSpikevax modernaEero poukkaAnders hviidEuropean medicines agencyFinnish medical foundationSanofi aventisNiklas worm andersson

Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses

Objective To investigate the comparative vaccine effectiveness of heterologous booster schedules (ie, three vaccine doses) compared with primary schedules (two vaccine doses) and with homologous mRNA vaccine booster schedules (three vaccine doses) during a period of omicron predominance. Design Population based cohort analyses. Setting Denmark, Finland, Norway, and Sweden, 27 December 2020 to 31 December 2022. Participants All adults aged ≥18 years who had received at least a primary vaccination schedule of AZD1222 (Oxford-AstraZeneca) or monovalent SARS-CoV-2 wild type (ancestral) strain based mRNA vaccines BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), in any combination. Main outcome measures The main outcome measure was country combined risks of covid-19 related hospital admission and death with covid-19 and additional outcomes of covid-19 related admission to an intensive care unit and SARS-CoV-2 infection. During a period of omicron predominance, these outcomes were com

United kingdomKarolinska institutetMorten andersenLars christian lundUlrike baumCoronavac sinovacAnders hviidJostein starrfeltEero poukkaJesper hallasNicklas pihlstrHinta meijerinkS janssen johnsonJesper kjChristian holm hansenMathijs goossens

Menopause and Long COVID: What Women Should Know

British researchers have newly noted that women at midlife who have long COVID seem to get specific, and severe, symptoms, including brain fog, fatigue, new-onset dizziness, and difficulty sleeping.

Uppsala lanUnited kingdomSan franciscoUnited statesRickard ljungJoannv pinkertonClare flanneryLed research collaborative university of californiaAmerican menopause societyYale school of medicineNewson health researchAmerican medical associationSwedish medical products agencyMedscape coronavirus resource centerMassachusetts institute of technology patientUniversity of virginia